Jaguar health launches fda-approved oral mucositis prescription product gelclair in the u.s.

Gelclair ® is the company's third commercialized prescription product oral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most significant adverse event in oncology according to a national comprehensive cancer network task force severe mucositis/pharyngitis occurred in 70% of head and neck cancer patients in third-party study san francisco, ca / accesswire / october 16, 2024 / jaguar health, inc. (nasdaq:jagx) ("jaguar") today announced that jaguar family company napo pharmaceuticals ("napo") has initiated the commercial launch of the fda-approved oral mucositis prescription product gelclair in the u.s. "cancer is chaotic, because patients feel a loss of control - over their life, their treatment, and their supportive care needs," said catherine collis, jaguar's senior vice president of growth strategy. "jaguar's mission is to change patients' lives for the better, especially in the area of supportive care for complex disease states like cancer.
JAGX Ratings Summary
JAGX Quant Ranking